BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27029036)

  • 1. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
    Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
    Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
    Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
    Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
    Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
    Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
    Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
    Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
    Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
    Klapper W; Kreipe H
    Pathologe; 2015 Mar; 36(2):164-70. PubMed ID: 25809654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.
    Li Y; Beck RC; Moore EM
    Am J Clin Pathol; 2021 Sep; 156(4):634-643. PubMed ID: 33877292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes.
    Hansen JW; Westman MK; Sjö LD; Saft L; Kristensen LS; Ørskov AD; Treppendahl M; Andersen MK; Grønbaek K
    Am J Hematol; 2016 Dec; 91(12):1234-1238. PubMed ID: 27717004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
    Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
    Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies.
    Ivanova M; Shivarov V; Pavlov I; Lilakos K; Naumova E
    Mol Diagn Ther; 2016 Feb; 20(1):27-32. PubMed ID: 26476543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.
    Montes-Moreno S; Routbort MJ; Lohman EJ; Barkoh BA; Kanagal-Shamanna R; Bueso-Ramos CE; Singh RR; Medeiros LJ; Luthra R; Patel KP
    PLoS One; 2018; 13(9):e0204218. PubMed ID: 30222780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.